Yahoo Finance What Happened in the Stock Market Today
Stocks opened the week with strong gains Monday. The Dow Jones Industrial Average (DJINDICES: ^DJI) and the S&P 500 (SNPINDEX: ^GSPC) both set record highs.
Today's stock market
Index | Percentage Change | Point Change |
|---|---|---|
Dow | 0.55% | 142.88 |
S&P 500 | 0.81% | 22.67 |
Data source: Yahoo! Finance.
News of a couple major acquisitions had biotech stocks soaring today; the SPDR S&P Biotech ETF (NYSEMKT: XBI) was up a huge 5.6%. Energy shares also rose, with the SPDR S&P Oil & Gas Exploration & Production ETF (NYSEMKT: XOP) gaining 2.5%.
As for individual stocks, Halliburton (NYSE: HAL) help boost energy shares with an upbeat earnings report, and Sanofi (NYSE: SNY) announced the purchase of blood disease specialist Bioverativ (NASDAQ: BIVV).
Image source: Getty Images.
Strong oil prices boost Halliburton results
Oil services company Halliburton reported a strong fourth quarter and offered an optimistic outlook for 2018, lifting shares 6.4%. Revenue of $5.94 billion was up 48% from the period last year and 9% from Q3. Adjusted earnings per share from continuing operations jumped to $0.53. Analysts were expecting adjusted EPS of $0.46 on revenue of $5.63 billion. Halliburton took charges of $385 million for delays in collecting payments in Venezuela and $882 million on a writedown of tax assets due to the new tax law. Including these one-time, non-cash charges, the company posted a GAAP loss of $0.92 per share.
Higher oil prices have resulted in increased drilling activity in North America, where Halliburton gets most of its revenue. Revenue in North America was up 7% from last quarter to $3.4 billion. But international sales were strong, too, growing 11% sequentially, led by higher drilling activity in the Middle East and Latin America.
Looking forward, CEO Jeff Miller said, "I am optimistic about what I see in 2018. Commodity prices are supportive of increasing activity in North America and I am encouraged by the increase in tender activity and the positive discussions we are having with our international customers."
The recent rebound in oil prices has boosted oil stocks since mid-August. But the strength of Halliburton's business in Q4 beat the estimates of even the most optimistic analysts.
Sanofi pays a generous price to acquire Bioverativ
Shares of biotech Bioverativ soared nearly 62% today after French drug giant Sanofi announced it was acquiring the company for $105 per share in an $11.6 billion, all-cash deal. Sanofi stock fell 3.1% on the news.
Bioverativ became public a little under a year ago when Biogen spun off its hemophilia business. The company is profitable and growing, thanks to sales of hemophilia drugs Eloctate and Alprolix, and had revenue growth of 27% and net income of $68 million last quarter. Sanofi believes the acquisition will be immediately accretive to business earnings per share.
"With Bioverativ, a leader in the growing hemophilia market, Sanofi enhances its presence in specialty care and leadership in rare diseases, in line with its 2020 Roadmap, and creates a platform for growth in other rare blood disorders," commented Olivier Brandicourt, Sanofi's CEO.
The price tag on the deal, a 64% premium to Friday's closing price, certainly raised some eyebrows. Analysts estimate Bioverativ brought in $1.16 billion in revenue in 2017, meaning that Sanofi is buying the company for right around 10 times sales, a hefty price but not too far out of line with other recent biotech buyouts. With competition heating up in a hemophilia market that Sanofi estimates to be $10 billion annually, the move may prove to be prudent in the long run. In any case, it is the latest evidence that M&A activity is heating up in the biotech space.
More From The Motley Fool
Jim Crumly owns shares of Biogen and Bioverativ. The Motley Fool recommends Biogen and Bioverativ. The Motley Fool has a disclosure policy.
